Article
IVAX Corp. joins the growing number of drug manufacturers to market its version of brimonidine tartrate ophthalmic solution 0.2%.
Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Integrating imaging modalities for early detection of key microscopic abnormalities in diabetic retinopathy
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy